Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Incyte (INCY) PT Raised to $98 at Mizuho Securities
October 30, 2019 8:03 AM EDTMizuho Securities analyst Mara Goldstein raised the price target on Incyte (NASDAQ: INCY) to $98.00 (from $95.00) while maintaining a Buy rating.
The analyst commented, "We continue to like INCY based on the combination of cash flow generated by JAKAFI and opportunities from potential... More
Incyte (INCY) Tops Q3 EPS by 17c, Revenues Beat; Raises FY19 Jakafi Revenue Outlook
October 29, 2019 7:12 AM EDTIncyte (NASDAQ: INCY) reported Q3 EPS of $0.82, $0.17 better than the analyst estimate of $0.65. Revenue for the quarter came in at $551.58 million versus the consensus estimate of $534.88 million.
Total product and royalty revenues of $534 million (+24% vs. Q3 2018) and Jakafi® (ruxolitinib) revenues of $433 million (+25% vs. Q3 2018) for the quarter ended September 30, 2019;... More